

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 71

[Airspace Docket No. 97-AWA-4]

RIN 2120-AA66

Establishment of Class C Airspace and Revocation of Class D Airspace, Austin-Bergstrom International Airport, TX; and Revocation of Robert Mueller Municipal Airport Class C Airspace; TX

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Final rule; delay of effective date.

SUMMARY: On February 11, 1999, the FAA published a final rule establishing a Class C airspace area and revoking the Class D airspace area for the Austin-Bergstrom International Airport, TX. The rule also revoked the Class C airspace area for the Robert Mueller Municipal Airport, TX. In view of the delay in the opening date of the new Austin-Bergstrom International Airport, TX, this action delays the rule's effective date until May 23, 1999.

EFFECTIVE DATE: Effective April 30, 1999, the effective date of the Final Rule at 64 FR 6793 is delayed until 0601 UTC, May 23, 1999.

FOR FURTHER INFORMATION CONTACT: Sheri Edgett Baron, Airspace and Rules Division, ATA-400, Office of Air Traffic Airspace Management, FAA, 800 Independence Avenue, SW., Washington, DC 20591; telephone: (202) 267-8783.

SUPPLEMENTARY INFORMATION: On February 11, 1999, the FAA published a final rule establishing a Class C airspace area and revoking the Class D airspace area for Austin-Bergstrom International Airport, TX (64 FR 6793). The rule also revoked the Class C airspace area for Robert Mueller Municipal Airport, TX. Due to construction delays, the official opening of the Austin-Bergstrom International Airport has been delayed until May 23, 1999. Accordingly, the effective date of the establishment and revocation of the related Class C and Class D airspace areas is postponed until the opening of the new airport.

Because the public needs to be made aware of this postponement immediately, notice and public procedure are impracticable and good cause exists for making the postponement effective in less than 30 days.

In consideration of the foregoing, effective April 30, 1999, the effective

date of the final rule establishing the Class C airspace area and revoking the Class D airspace area for Austin-Bergstrom International Airport; and revoking the Class C airspace area for Robert Mueller Municipal Airport (64 FR 6793; February 11, 1999) is delayed from May 2, 1999, to May 23, 1999.

Issued in Washington, DC, on April 20, 1999.

Reginald C. Matthews,

Acting Program Director for Air Traffic Airspace Management.

[FR Doc. 99-10964 Filed 4-29-99; 8:45 am]

BILLING CODE 4910-13-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 5

Delegation of Authority and Organization; Center for Veterinary Medicine; Technical Amendment

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule; technical amendment.

SUMMARY: The Food and Drug Administration (FDA) is amending the regulation to reflect a redelegation of authority with respect to approval of supplemental new animal drug applications to the Director, Division of Manufacturing Technology, Office of New Animal Drug Evaluation, Center for Veterinary Medicine (CVM). This action is necessary to ensure the continued accuracy of the regulation.

EFFECTIVE DATE: December 22, 1998.

FOR FURTHER INFORMATION CONTACT:

Carol Haley, Center for Veterinary Medicine (HFV-6), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-594-1682;

Donna G. Page, Division of Management Systems and Policy (HFA-340), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-4816.

SUPPLEMENTARY INFORMATION: In the Federal Register of December 22, 1998 (63 FR 70650), FDA amended the regulation for redelegations of authority to incorporate provisions for feed mill licensing and to update positions and component titles associated with the authorities under § 5.83 (21 CFR 5.83). The regulation in § 5.83(c)(1) reflected a redelegation with respect to approval of certain supplemental new animal drug

applications to the position title "Director, Division of Human Food Safety, Office of New Animal Drug Evaluation, CVM." The correct position title to which these functions should have been redelegated is the "Director, Division of Manufacturing Technologies, Office of New Animal Drug Evaluation, CVM," because that office is responsible for supplemental applications for manufacturing. Therefore, the redelegation to the "Director, Division of Human Safety Office of New Animal Drug Evaluation, CVM" has been amended and a new redelegation made to the "Director, Division of Manufacturing Technologies, Office of New Animal Drug Evaluation, CVM." The regulation in § 5.83(c)(1) has been revised to reflect this redelegation. Further redelegation of authorities is not authorized at this time. Authority delegated to a position may be exercised by a person officially designated to serve in such position in an acting capacity or on a temporary basis.

List of Subjects in 21 CFR Part 5

Authority delegations (Government agencies), Imports, Organization and functions (Government agencies).

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR part 5 is amended to read as follows:

PART 5—DELEGATIONS OF AUTHORITY AND ORGANIZATION

1. The authority citation for 21 CFR part 5 continues to read as follows:

Authority: 5 U.S.C. 504, 552, App. 2; 7 U.S.C. 138a, 2271; 15 U.S.C. 638, 1261-1282, 3701-3711a; 15 U.S.C. 1451-1461; 21 U.S.C. 41-50, 61-63, 141-149, 321-394, 467f, 679(b), 801-886, 1031-1309; 35 U.S.C. 156; 42 U.S.C. 241, 242, 242a, 242l, 242n, 243, 262, 263, 264, 265, 300u-300u-5, 300aa-1; 1395y, 3246b, 4332, 4831(a), 10007-10008; E.O. 11921, 41 FR 24294, 3 CFR 1977 Comp., p. 124-131; E.O. 12591, 52 FR 13414, 3 CFR, 1988 Comp., p. 220-223.

2. Section 5.83 is amended by revising paragraph (c)(1) to read as follows:

§ 5.83 Approval of new animal drug applications, medicated feed mill license applications, and their supplements.

* * * * *

(c) * * *

(1) The Director, Division of Manufacturing Technologies, Office of New Animal Drug Evaluation, CVM.

* * * * *